Onconetix (NASDAQ:ONCO) Posts Earnings Results

Onconetix (NASDAQ:ONCO) posted its quarterly earnings data on Friday. The company reported $12.58 earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.30 million during the quarter. Onconetix had a negative return on equity of 632.63% and a negative net margin of 4,011.43%.

Onconetix Stock Performance

Shares of ONCO traded down $0.03 during mid-day trading on Friday, hitting $0.54. The company’s stock had a trading volume of 36,019 shares, compared to its average volume of 390,874. The stock’s 50-day moving average is $1.19 and its two-hundred day moving average is $2.24. The firm has a market capitalization of $841,805.00, a PE ratio of 0.05 and a beta of 3.51. Onconetix has a one year low of $0.44 and a one year high of $14.86.

Institutional Trading of Onconetix

An institutional investor recently bought a new stake in Onconetix stock. Citadel Advisors LLC acquired a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned approximately 1.00% of Onconetix at the end of the most recent reporting period. 23.89% of the stock is owned by institutional investors and hedge funds.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.